Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Boehringer Ingelheim appoints Gagandeep Singh, former AstraZeneca MD, as Head of Human Pharma India
Singh has been appointed as Managing Director and head of the pharma business vertical for the Indian market. His appointment will come into effect on July 10.
- By Pooja Chaturvedi Sah
- New Delhi
- Jun 28, 2023
Drug firm Boehringer Ingelheim has appointed Gagandeep Singh as Managing Director and head of the pharma business vertical for the Indian market. His appointment will come into effect on July 10.
He will also join the Board of Boehringer Ingelheim India, the company said in a statement.
Singh was Managing Director for India and Africa Cluster Head at AstraZeneca Pharma India and had resigned last December.
In his new role, Singh succeeds Vani Manja, who moved to Boehringer Ingelheim UK in February 2023. During the transition, Sandip Agrawal, Director of Finance and Administration, took over the added responsibility of Interim Managing Director.
Mohammed Tawil, Regional Managing Director and Head of Human Pharma (India, Middle East, Turkey, and Africa) at Boehringer Ingelheim said, “Gagandeep's passion for fostering a customer-focused culture and his experience across complex health ecosystems, will be invaluable to the organization as we continue to strengthen our strategic and sustainability commitment to India”.
Boehringer Ingelheim which has three business areas -- Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing, has been operating in India since 2003.